Abstract
This study investigates the prevalence of congenital cytomegalovirus (CMV), Rubella, and Herpes Simplex Virus-2 (HSV-2) infections in infants. Congenital viral infections remain a significant cause of neonatal morbidity, and early identification is critical for clinical management and long-term outcomes.
Congenital viral infections represent a significant area of concern in neonatal medicine, as they can lead to serious long-term health outcomes for affected infants. Among the most studied pathogens in this context are cytomegalovirus, rubella, and herpes simplex virus type 2. These infections may be transmitted from mother to child during pregnancy or delivery, often with subtle or no symptoms at birth. Early detection through serological screening and molecular diagnostic techniques allows clinicians to initiate timely interventions, potentially reducing the burden of morbidity associated with these conditions. Ongoing research continues to refine diagnostic protocols and explore therapeutic options that improve prognosis for affected newborns.
The role of biomarkers in the early identification of congenital infections has gained increasing attention in recent years. Biomarkers can provide valuable clues about the presence and severity of an infection before clinical signs become apparent. In the context of neonatal care, inflammatory markers and pathogen-specific antibodies are commonly used to guide diagnostic decisions. When combined with advanced imaging and clinical assessment, these tools help healthcare professionals differentiate between infectious and non-infectious causes of neonatal illness. Continued study in this area promises to enhance the accuracy and speed of diagnosis, supporting better outcomes for vulnerable infants worldwide.
Clinical management of congenital infections requires a multidisciplinary approach involving neonatologists, infectious disease specialists, and microbiologists. Treatment strategies vary depending on the specific pathogen involved, the timing of infection, and the severity of symptoms at presentation. Antiviral therapies, supportive care, and long-term monitoring are often key components of a comprehensive management plan. In many healthcare settings, prevention through maternal screening and vaccination programs remains the most effective strategy for reducing the incidence of these infections. Public health initiatives that promote awareness and access to prenatal care play a crucial role in this effort.
The global burden of congenital infections varies significantly across different regions, influenced by factors such as maternal immunity rates, vaccination coverage, and healthcare infrastructure. In countries where rubella vaccination programs are well established, the incidence of congenital rubella syndrome has declined dramatically. However, challenges remain in resource-limited settings where access to diagnostic testing and specialized care may be restricted. International collaboration and knowledge sharing among researchers and clinicians have contributed to improved understanding of disease patterns and treatment outcomes. Continued investment in healthcare systems and preventive medicine remains essential for reducing the impact of these preventable infections.
Aims
To determine the seroprevalence of CMV, Rubella, and HSV-2 among infants presenting with suspected congenital infections, and to evaluate the diagnostic utility of laboratory methods in this population.
Material and methods
Serum samples from infants with clinical suspicion of congenital infection were tested using standard serological assays. Data were analysed to assess infection rates and associated clinical presentations.
Results
The study identified measurable seropositivity for the three target viruses among the infant cohort, with CMV being the most frequently detected pathogen. Co-infections were observed in a subset of cases.
Conclusion
Congenital CMV, Rubella, and HSV-2 infections continue to pose a diagnostic challenge. Laboratory screening plays a vital role in early detection and should be integrated into routine neonatal care protocols where clinically indicated.